HIV, HCV and overdose prevention for Human Immunodeficiency Virus Infection
This trial is testing whether a targeted, peer-driven intervention can reduce HIV and HCV transmission, as well as overdose risk behaviors, among people who inject drugs.
- Human Immunodeficiency Virus (HIV) Infection
- Drug Overdose
- Hepatitis C
2 Primary · 2 Secondary · Reporting Duration: 6 months
2 Treatment Groups
1 of 2
1 of 2
285 Total Participants · 2 Treatment Groups
Primary Treatment: HIV, HCV and overdose prevention · No Placebo Group · N/A
Who is running the clinical trial?
Age 18+ · All Participants · 1 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
|Lighthouse Studies at Peer Point||100.0%|
What portion of applicants met pre-screening criteria?
|Did not meet criteria||100.0%|
Frequently Asked Questions
Are there still openings for participation in this clinical trial?
"Affirmative. The details on clinicaltrials.gov confirm that the trial, initially posted April 30th 2022, is presently enrolling participants. About 285 individuals must be recruited from a single medical centre." - Anonymous Online Contributor
How many participants are eligible to take part in this clinical research?
"Affirmative. Per information accessible on clinicaltrials.gov, this study is currently looking for participants to enrol. The trial was first posted April 30th 2022 and most recently updated September 7th 2022; the research seeks 285 volunteers from a single location." - Anonymous Online Contributor